TGF-beta activated kinase 1 binding protein 2 (TAB2)

TGF-beta activated kinase 1 binding protein 2 (TAB2) is a signal transduction adapter protein essential for the activation of the MAPK/JNK and NF-kappaB pathways in response to interleukin-1 and other pro-inflammatory stimuli[1][7]. It interacts with polyubiquitin chains (Lys63-linked) and forms functional complexes with kinases like MAP3K7 (TAK1) and TRAF6, linking these components in key signaling cascades involved in inflammation, immunity, and development[1][5]. TAB2 is critical for heart development, and mutations can cause congenital heart defects and related syndromes[7][1]. While not a direct target of any approved drugs, it plays a central scaffolding role in cytokine and stress response pathways that are therapeutically targeted in inflammatory and oncologic diseases[1][4][7].

Other names

MAP3K7IP2TGF-beta-activated kinase 1 and MAP3K7-binding protein 2TAB2_HUMANTGF-beta activated kinase 1 (MAP3K7) binding protein 2

Drugs targeting upstream or downstream kinases in the MAPK or NF-kappaB pathways may modulate TAB2-mediated signaling, typically by inhibiting kinase activity or blocking downstream inflammatory responses[1][7].